公司資料
InMed 股價、新聞與催化劑
- 股票代碼:
- INM
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- Canada and listed in the U
股票表現
1.35 USD (-0.74%)
收盤價
最後更新: 2026年10月1日
5.04M USD
市值
股價為何變動
截至 2026年10月1日，INM 下跌 0.74%，收於 $1.35。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Small-Molecule Drug Portfolio Company
InMed Pharmaceuticals has developed cannabinoid-related and other small-molecule candidates for neurological, ophthalmic, and dermatologic diseases. The company is seeking strategic transactions for its legacy development programs.
INM-901 for Alzheimer's Disease
INM-901 is a small-molecule candidate being explored for Alzheimer's disease. Preclinical work has evaluated potential effects on neuroinflammation, neuronal function, and disease-related pathology.
INM-089 for Dry AMD
INM-089 is being developed for dry age-related macular degeneration. The program is intended to address retinal degeneration through a differentiated small-molecule mechanism.
INM-755 Dermatology Program
INM-755 is a topical candidate that has been studied in dermatologic conditions, including symptoms associated with epidermolysis bullosa. It remains part of the portfolio available for licensing or other strategic development.
Transition from BayMedica
InMed discontinued operations at BayMedica, its rare-cannabinoid manufacturing subsidiary. The remaining strategy emphasizes monetization, licensing, or transfer of the pharmaceutical assets rather than maintaining a vertically integrated commercial cannabinoid business.
未來催化劑
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。